Abbott Laboratories (NYSE:ABT) Stock Acquired Rep. Richard McCormick

Representative Richard McCormick (Republican-Georgia) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on March 19th. The trade occurred in the Representative’s “GROWTH PARTNERS IRA” account.

Representative Richard McCormick also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Automatic Data Processing (NASDAQ:ADP) on 3/19/2026.
• Sold $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 3/19/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/19/2026.
• Sold $1,001 – $15,000 in shares of Automatic Data Processing (NASDAQ:ADP) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of BlackRock (NYSE:BLK) on 3/19/2026.
• Sold $1,001 – $15,000 in shares of L3Harris Technologies (NYSE:LHX) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 3/19/2026.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 3/19/2026.

Abbott Laboratories Stock Up 1.8%

Abbott Laboratories stock opened at $103.70 on Thursday. Abbott Laboratories has a fifty-two week low of $100.88 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The firm has a 50 day moving average price of $109.17 and a 200 day moving average price of $120.35. The company has a market capitalization of $180.61 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Daiwa Securities Group dropped their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Evercore dropped their target price on shares of Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating for the company in a report on Monday. Citigroup dropped their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Royal Bank Of Canada dropped their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $134.58.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last three months. 0.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. State Street Corp increased its holdings in shares of Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares during the last quarter. Capital International Investors raised its position in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP raised its position in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors lifted its stake in Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Representative McCormick

Rich McCormick (Republican Party) is a member of the U.S. House, representing Georgia’s 7th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

McCormick (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 7th Congressional District. He declared candidacy for the 2026 election.

Rich McCormick lives in Suwanee, Georgia. McCormick served in the U.S. Marine Corps and the U.S. Navy. He earned an M.B.A. from National University and an M.D. from Morehouse School of Medicine. McCormick’s career experience includes working as an emergency medicine physician with Gwinnett Medical Center and Northside Hospital, a Marine officer instructor with Georgia Tech and Morehouse College, and a pilot.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.